Preparing for China · patient guide

Myelodysplastic syndrome care in China: what to prepare

Preparation for myelodysplastic syndrome (MDS) care in China starts with a complete, legible record set: blood counts over time, bone marrow reports and slides, cytogenetics and molecular results, transfusion and infection history, and every treatment already given. The receiving haematology team decides whether the diagnosis and risk assessment are complete, what further testing is needed, and which options fit. No overseas enquiry establishes eligibility, treatment availability or hospital acceptance.

Go to the practical guidance ↓
AI illustration: A clean desk with a notebook, pen, clipboard, glass of water, and a potted plant near a window with a cityscape view.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What an MDS review actually needs from your records

MDS is not one condition. It is a group of bone marrow disorders in which blood cell production is ineffective, and the World Health Organization classification and the International Prognostic Scoring System separate subtypes with very different outlooks and management. That is why a haematologist reviewing an overseas patient cannot work from a single low haemoglobin value or a one-line diagnosis. The review depends on the marrow morphology, the blast proportion, the karyotype and, increasingly, somatic mutations.

The practical consequence is that your preparation should aim to let a new team reconstruct the diagnostic work-up, not just confirm that MDS was mentioned. Ask your current haematologist which documents underpin the diagnosis and the risk category, and request copies rather than summaries. If a report exists only in a hospital portal, download it while you still have access.

A useful record set covers four areas: the diagnostic evidence, the disease course over time, the treatment history and the patient's current clinical state. Each answers a different question for the receiving clinician, and gaps in any one of them tend to produce a request for more information rather than a plan.

  • Sequential full blood counts with dates, not only the most recent result
  • Bone marrow aspirate and trephine biopsy reports, with the blast percentage stated
  • Cytogenetics or karyotype report and any fluorescence in situ hybridisation results
  • Molecular or next-generation sequencing panels if performed, with the variant list
  • Flow cytometry or immunohistochemistry used to support the diagnosis
  • Transfusion records: red cell and platelet units, dates and any reactions
  • Infection history, including febrile episodes and neutropenic sepsis
  • Every MDS-directed therapy with drug, dose, start and stop dates and reason for stopping

Marrow slides and pathology material: ask before you travel

Reports alone may not be enough. A receiving haematology service may want to review the original bone marrow slides, trephine block or peripheral blood films, because the blast count and dysplasia assessment are observer-dependent and central review can change the classification. Whether a particular Chinese hospital will accept outside slides, and in what format, is a question for that hospital rather than a general rule.

If review is possible, the logistics matter. Unstained slides and paraffin blocks are physical objects that usually need to travel with documentation, and some laboratories release them only on request, sometimes as recuts rather than originals. Ask your pathology department what it can release, how long that takes and whether it will issue recut sections. Keep the original diagnostic report with the material so the receiving pathologist can compare.

Do not assume that sending a PDF of the report substitutes for the material, and do not assume the opposite either. Put the question in writing to the hospital or the coordinating team: which pathology items does the treating haematologist need, and will they accept digital images or scanned slides in place of glass? The answer determines what you request from your laboratory before you leave.

The clinical questions that shape an MDS plan

MDS management ranges from observation with regular blood counts through growth factor support, transfusion programmes and disease-modifying drugs to allogeneic stem cell transplantation in selected patients. Which applies depends on the subtype, the risk score, the patient's age and fitness, comorbidities and preferences. A new team will therefore want to know not only what has been tried, but why each option was chosen or declined.

Transfusion history deserves particular attention. The number of red cell units received, the interval between transfusions and whether iron overload has been assessed all inform the discussion. So does any history of platelet transfusion refractoriness. Bring the actual records; a patient estimate of "about every three weeks" is less useful than dated entries.

Current medicines need an accurate list, including supportive drugs, antimicrobial prophylaxis, iron chelation and any growth factors, with doses. Do not stop or change any medicine in preparation for travel. Prescribing and any adjustment belong to licensed clinicians, and questions about continuing a specific product during a trip should go to the team that prescribes it.

It also helps to write down the patient's own priorities in plain language: fewer hospital visits, avoiding a particular treatment, maintaining independence, or exploring transplant. A haematologist can address a stated goal; a vague request for "the best treatment" is harder to answer usefully.

Transplant, trials and newer drugs are separate decisions

Patients often contact a service in China hoping to access a specific therapy they have read about. It is important to separate three different questions: whether the treatment is clinically appropriate for this patient, whether a particular hospital can provide it, and whether the patient is eligible for a specific programme. A records review can begin to address the first. It does not establish the second or third.

Allogeneic transplantation is a potentially curative option for some patients with higher-risk MDS, but it carries substantial risk of treatment-related complications, graft-versus-host disease and mortality, and suitability depends on disease status, donor availability, age, organ function and comorbidity. A remote opinion cannot confirm that a transplant will proceed. Ask the treating team directly how they assess fitness, what donor options exist for you and what the realistic alternatives are.

Clinical trials and newer agents have their own eligibility criteria, which are defined in the protocol and assessed by the trial team. An enquiry, a records review or a specialist appointment does not constitute enrolment, and no service can promise access to a named drug or trial. If a specific therapy matters to you, ask which institution runs the relevant programme and what documentation its team requires before any eligibility discussion.

Related treatment reference

Practical preparation and what to confirm in writing

Once the records are assembled, translate the key documents into English or Chinese as the receiving team requires, and keep a one-page chronology at the front: diagnosis date, subtype if stated, risk category if stated, treatments in order, transfusions and current medicines. A clinician reading a folder of twenty reports will appreciate that summary, but it must not replace the underlying documents.

Several practical points are hospital-specific and should be confirmed rather than assumed. Ask whether the haematology service has an international department, what language support is available for consultations, how many visits an assessment is likely to involve, and how results and follow-up plans are communicated. Ask what the written estimate covers and which charges are paid to the hospital separately. Do not rely on a general statement that everything is included.

Travel planning should follow clinical advice, not precede it. Patients with low blood counts, active infection or recent treatment may need assessment locally before any journey, and fitness to travel is a clinical judgement. If symptoms worsen, seek local medical care rather than continuing with overseas arrangements.

For an initial enquiry, a short summary is enough: the diagnosis as stated, the main question, and a list of the records you hold. Detailed records can follow once the team confirms what is relevant. An initial case review is free and does not commit you to a proxy consultation, which is optional and separate.

A realistic next step

Start by requesting the diagnostic marrow report, cytogenetics, molecular results and a dated blood count history from your current haematologist, and ask what pathology material can be released. Then send a brief summary through the enquiry route and ask which of those items the receiving haematology team needs first. That exchange, rather than a purchased package, is what turns a general hope of treatment abroad into a specific, answerable clinical question.

Keep expectations calibrated. The hospital decides suitability and acceptance, the treating clinicians decide diagnosis and treatment, and any estimate of cost or timeline is individual. Preparation improves the quality of the conversation; it does not guarantee an outcome.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. Myelodysplastic Syndromes Treatment - NCI

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.